University of Alabama Birmingham
Investigating pathological features of TDP-43 in neurodegeneration
Abstract
dc:description.abstractTransactivation response element (TAR) DNA binding protein of 43 kDa (TDP-43) is an essential RNA-binding protein required for coordinating multiple aspects of RNA metabolism. TDP-43 is multifunctional in both nuclear and cytoplasmic cellular compartments and shuttling in and out of the nucleus is an integral part of TDP-43 function. Nuclear depletion and cytoplasmic accumulation of TDP-43, aggregation of TDP-43 within inclusion bodies in the cytoplasm, and aberrant post-translational modifications and truncation of TDP-43 are all common pathological features of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer’s disease (AD). Localization of TDP-43 is connected to essential functions such as alternative splicing regulation and microRNA processing, and ultimately, loss of TDP-43 function contributes to cell death. TDP-43 pathology is present in 97% of ALS patients, yet a clear understanding of how pathological features of TDP-43 found in neurodegenerative disease are cytotoxic remain unknown. This is due in part to a lack of understanding of how compartmentalization and trafficking of TDP-43 throughout the cell is regulated. In this dissertation, I outline novel findings in the mechanism of regulated transport of TDP-43 from the nucleus to the cytoplasm under cell stress conditions that model neurodegeneration. I investigate two pathways that influence TDP-43 localization. One involves hyperactivation of poly(ADP-ribose) polymerase 1 (PARP1) as a DNA damage response pathway that contributes to neurodegeneration. The other is a nuclear export pathway involving the nuclear transport receptor exportin-1 (XPO1). This dissertation describes a novel mechanism where XPO1, which does not participate in nuclear export of TDP-43 under healthy conditions, becomes the dominant nuclear export pathway for TDP-43 in cell stress conditions where PARP1 is hyperactivated. These finds provide support and rationale for investigating clinically approved PARP1 and XPO1 inhibitors for the treatment of neurodegenerative diseases with TDP-43 pathology.
Degree
thesis:*- Level thesis:degree_level
- Dissertation
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Marcus, Joshua Mathew
- Contributors dc:contributor
-
- Shaida A Andrabi
- Lori L McMahon
- Charles F Falany
- Andrew B West
Subjects
dc:subject × 1Identifiers
dc:identifier.*- Repository record dc:identifier
- https://digitalcommons.library.uab.edu/etd-collection/852